<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093727</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-LAN-2013-39</org_study_id>
    <nct_id>NCT03093727</nct_id>
  </id_info>
  <brief_title>Characterization of Pulmonary Langerhans Cell Histiocytosis</brief_title>
  <official_title>Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very recent studies indicate that a high percentage of HCL, about 50%, have mutations in the
      B-RAF oncogene. The development of ultrasensitive methodologies capable of identifying these
      mutations in bronchoalveolar lavage will represent a significant advance in the diagnosis and
      treatment of these patients. An undetermined percentage of HCL does not present mutations in
      B-RAF. Consequently, the deep genetic analysis, through the use of techniques of massive
      sequencing, can favor the identification of new alterations that contribute to the
      development of the disease.

      We hypothesized that patients with HCL may present a different inflammatory state to healthy
      subjects or smokers, allowing us to identify new biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to expand the genetic and pathophysiological knowledge of
      this disease. For this, the following points will be developed:

        -  Identification of mutations in the B-RAF oncogene in Spanish patients with pulmonary
           LCHF.

        -  Development of ultrasensitive genetic analysis methods capable of identifying mutations
           in B-RAF in bronchoalveolar lavage (BAL) samples.

        -  To determine if patients with mutations in the B-RAF oncogene present distinct clinical,
           radiological and / or functional characteristics compared to those with absence of the
           mutation.

        -  Characterization of the inflammatory profile of patients with HPCL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Identification of mutations in the B-RAF oncogene in patients with pulmonary Langerhans histiocytosis</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Langerhans Cell Histiocytoses</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Langerhans cell histiocytosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Men and women with no age limitation

          -  Established histiological diagnosis of histiocytosis of langerhans cells.

          -  HCLP-compatible clinical-radiological picture.

          -  Signed informed consent

        Exclusion criteria

          -  Non-acceptance of informed consent.

          -  Absence in clinical history of clinical, radiological and functional variables
             essential for the diagnosis of HLCP.

          -  Psychiatric disorder or limitation for study compression (including language,
             socio-cultural problem, etc.).

          -  Radiological findings suggestive of another chronic lung disease.

          -  Active respiratory infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Erika Delgado Espinoza</last_name>
      <email>CDelgadoE@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Diego Castillo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

